Cynosure, Inc. (CYNO)
-NasdaqGS 24.50 
0.83(3.51%) 1:30PM EDT - Nasdaq Real Time Price
| Prev Close: | 23.67 |
|---|
| Open: | 23.70 |
|---|
| Bid: | 24.42 x 200 |
|---|
| Ask: | 24.48 x 100 |
|---|
| 1y Target Est: | 36.50 |
|---|
| Beta: | 1.44 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 23.45 - 24.50 |
|---|
| 52wk Range: | 18.37 - 30.20 |
|---|
| Volume: | 236,248 |
|---|
| Avg Vol (3m): | 186,537 |
|---|
| Market Cap: | 397.22M |
|---|
| P/E (ttm): | 31.91 |
|---|
| EPS (ttm): | 0.77 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Cynosure Enters Oversold Territory (CYNO)at TheStreet(Mon, May 20)
- CYNOSURE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Thu, May 16)
- Investing In Increased Tattoo Removal With Cynosureat Seeking Alpha(Thu, May 16)
- CYNOSURE INC FinancialsEDGAR Online Financials(Wed, May 15)
- This Hedge Fund Just Overhauled Its Equity Portfolio; Should You Pay Attention?at Seeking Alpha(Sun, May 12)
- CYNOSURE INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Cramer: Buy Discover Financial, Allergan, and These 2 Stocks, But Sell Cynosureat Wall St. Cheat Sheet(Tue, May 7)
- Cynosure to Present at UBS Global Healthcare ConferencePR Newswire(Tue, May 7)
- [video] Lightning Roundat CNBC(Mon, May 6)
- Cynosure's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Apr 30)
- Cynosure Earnings: Here’s Why Investors Like These Resultsat Wall St. Cheat Sheet(Tue, Apr 30)
- Cynosure Inc. Earnings Call scheduled for 9:00 am ET todayCCBN(Tue, Apr 30)
- Cynosure Reports First-Quarter 2013 Financial ResultsPR Newswire(Tue, Apr 30)
- Q1 2013 Cynosure Inc. Earnings Release - Before Market OpenCCBN(Tue, Apr 30)
- CYNOSURE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue, Apr 30)
Key Statistics
| Forward P/E (1 yr): | 19.87 |
|---|
| P/S (ttm): | 2.40 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.74 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.18 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | 0.38 |
|---|
Business Summary
Cynosure, Inc. develops, manufactures, and markets aesthetic treatment systems primarily to the dermatology, plastic surgery, and general medical markets.
View More